A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2025 and June 30, 2024 is as follows (in thousands):


Six Months Ended June 30, 2025	Contingent Consideration Liability Related to Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2025	$	12,968	$	2,686	$	3	54,000		69,657
Payment	(5,000)		—		—		(18,075)		(23,075)
Change in fair value of contingent consideration liabilities	(627)		(1,451)		—		1,875		(203)
Balance as of June 30, 2025	7,341		1,235		3		37,800		46,379

Short-Term - Accrued expenses and other liabilities	$	3,579	$	—	$	—	$	17,700	$	21,279
Long-Term - Other liabilities	3,762		1,235		3		20,100		25,100
Total	7,341		1,235		3		37,800		46,379


Six Months Ended June 30, 2024	Contingent Consideration Liability Related to Acquisition of:
	Arkis (1)		Derma Sciences (2)		ACell (2)		Surgical Innovations Associates (SIA), Inc. (2)		Total
Balance as of January 1, 2024	$	15,755	$	2,557	$	300	$	68,700	87,312
Payment							(12,400)		(12,400)
Change in fair value of contingent consideration liabilities	(934)		75		—		3,200		2,341
Balance as of June 30, 2024	$	14,821	$	2,632	$	300	$	59,500	77,253

Short-Term - Accrued expenses and other liabilities	$	8,244	$	—	$	—	$	19,200	$	27,444
Long-Term - Other liabilities	6,577		2,632		300		40,300		49,809
Total	14,821		2,632		300		59,500		77,253